目的 探討腎炎康復片聯(lián)合布美他尼治療慢性腎小球腎炎的臨床療效。方法 選取2020年2月—2022年2月界首市人民醫(yī)院收治的87例慢性腎小球腎炎患者，按照隨機數(shù)字表法將所有患者分成對照組（44例）和治療組（43例）。對照組口服布美他尼片，初始劑量0.5～2 mg/d，必要時間隔4～5 h可重復1次，每天最大劑量為10～20 mg。治療組在對照組治療的基礎上口服腎炎康復片，2.4 g/次，3次/d。兩組均連續(xù)治療8周。觀察兩組的臨床療效和頭暈目眩、腰膝酸痛、面浮肢腫、食少納呆、夜尿頻多、疲倦乏力改善時間，比較兩組治療前后腎功能指標和尿常規(guī)指標的變化情況。結(jié)果 經(jīng)治療，治療組總有效率是97.67%，顯著高于對照組的81.82%（P＜0.05）。經(jīng)治療，治療組頭暈目眩、腰膝酸痛、面浮肢腫、食少納呆、夜尿頻多、疲倦乏力等臨床癥狀改善時間均短于對照組（P＜0.05）。經(jīng)治療，兩組24 h尿總蛋白（24 h Upro）、血肌酐（Scr）、尿素氮（BUN）、尿白蛋白排泄率（UAER）均較同組治療前顯著降低（P＜0.05）；且治療后治療組腎功能指標低于對照組（P＜0.05）。經(jīng)治療，兩組患者尿液中白細胞、紅細胞計數(shù)均較同組治療前顯著降低（P＜0.05），治療后，治療組尿液中白細胞、紅細胞計數(shù)均低于對照組（P＜0.05）。結(jié)論 腎炎康復片聯(lián)合布美他尼治療慢性腎小球腎炎效果確切，可顯著改善患者腎功能指標，促進相關癥狀改善，值得臨床推廣應用。

Objective To investigate the clinical efficacy of Shenyan Kangfu Tablets combined with bumetanide in treatment of chronic glomerulonephritis. Methods A total of 87 patients with chronic glomerulonephritis admitted to Jieshu People's Hospital from February 2020 to February 2022 were selected, and all patients were divided into control group (44 cases) and treatment group (43 cases) according to random number table method. Patients in the control group were po administered with Bumetanide Tablets, the initial dosage was 0.5-2 mg/d, which could be repeated 4-5 h when necessary. The maximum dosage was 10-20 mg daily. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 2.4 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and improvement time of the clinical symptoms such as dizziness, waist and knee soreness, floating limb swelling, lack of food and lethargy, nocturnal frequent urination, and fatigue were observed in the two groups. The changes of renal function indexes and urine routine indexes before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 97.67%, significantly higher than that of the control group 81.82% (P < 0.05). After treatment, the improvement time of clinical symptoms such as dizziness, waist and knee soreness, floating limb swelling, lack of appetite, nocturnal frequent urination, and fatigue in treatment group was shorter than that in control group (P < 0.05). After treatment, 24 h Upro, Scr, BUN, and UAER in two groups were significantly decreased compared with before treatment (P < 0.05). The renal function index of the treatment group was lower than that of the control group (P < 0.05). After treatment, WBC and RBC counts in urine in two groups were significantly lower than before treatment (P < 0.05), and WBC and RBC counts in urine in treatment group were lower than control group after treatment (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with bumetanide has exact effect in treatment of chronic glomerulonephritis, and can significantly improve patients' renal function index and promote the improvement of related symptoms, which is worthy of clinical application.

R983

安徽省衛(wèi)生廳中醫(yī)藥科研計劃項目(2014zy93)